TCM
FATE icon

Tekla Capital Management’s Fate Therapeutics FATE Stock Holding History

Tekla Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-31,652
Closed -$784K – 175
2022
Q2 		$784K Hold
31,652
– – 0.03% 139
2022
Q1 		$1.23M Sell
31,652
-41,075
-56% -$1.59M 0.04% 139
2021
Q4 		$4.25M Hold
72,727
– – 0.14% 104
2021
Q3 		$4.31M Hold
72,727
– – 0.14% 112
2021
Q2 		$6.31M Sell
72,727
-77,616
-52% -$6.25M 0.21% 108
2021
Q1 		$12.4M Sell
150,343
-15,974
-10% -$1.53M 0.43% 62
2020
Q4 		$15.1M Sell
166,317
-51,145
-24% -$3.18M 0.53% 55
2020
Q3 		$8.69M Buy
217,462
+31,790
+17% +$1.11M 0.33% 74
2020
Q2 		$6.37M Buy
185,672
+20,000
+12% +$596K 0.24% 85
2020
Q1 		$3.68M Hold
165,672
– – 0.17% 103
2019
Q4 		$3.24M Hold
165,672
– – 0.12% 133
2019
Q3 		$2.57M Buy
165,672
+141,293
+580% +$2.71M 0.11% 121
2019
Q2 		$495K Buy
+24,379
New +$439K 0.02% 184

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Tekla Capital Management's FATE Position: Q3 2022 in Review

Tekla Capital Management sold out of Fate Therapeutics (FATE) in Q3 2022, closing a stake of 31,652 shares — an estimated $784K sold.

Tekla Capital Management first reported a position in FATE in Q2 2019 and held it in 13 quarters. The position peaked at $15.1M in Q4 2020. 239 funds tracked by Wall St. Rank hold FATE as of Q3 2022.

  • Tekla Capital Management reported no remaining Fate Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Tekla Capital Management sold 31,652 Fate Therapeutics shares in Q3 2022, an estimated $784K.
  • Tekla Capital Management first reported a position in Fate Therapeutics in Q2 2019 and held it in 13 quarters.
  • Tekla Capital Management's Fate Therapeutics position peaked at $15.1M in Q4 2020.
  • 239 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2022.

Based on Tekla Capital Management's 13F filing for Q3 2022, filed 1 Nov 2022.